| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/MDS.25136 |
| P698 | PubMed publication ID | 22927213 |
| P50 | author | George K Tofaris | Q56056700 |
| P2093 | author name string | George K Tofaris | |
| P2860 | cites work | PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1 | Q24297155 |
| Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies | Q24307627 | ||
| Collaborative Analysis of α-Synuclein Gene Promoter Variability and Parkinson Disease | Q57977634 | ||
| The familial Parkinsonism gene LRRK2 regulates neurite process morphology | Q24317613 | ||
| Hereditary early-onset Parkinson's disease caused by mutations in PINK1 | Q24337084 | ||
| Autophagic substrate clearance requires activity of the syntaxin-5 SNARE complex | Q24337387 | ||
| Disrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of α-synuclein and LRRK2 in the brain | Q24599233 | ||
| Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies | Q24606055 | ||
| Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro | Q24629968 | ||
| A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease | Q24633417 | ||
| Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. | Q24634577 | ||
| Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells | Q24651391 | ||
| LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model | Q24656256 | ||
| α-Synuclein in Lewy bodies | Q27860680 | ||
| Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity | Q27934988 | ||
| Chaperone-mediated autophagy markers in Parkinson disease brains | Q28115026 | ||
| Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase | Q28116395 | ||
| Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology | Q28131833 | ||
| Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice | Q28507051 | ||
| Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration | Q28587785 | ||
| The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia | Q29547174 | ||
| Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin | Q29547423 | ||
| Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy | Q29614178 | ||
| Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin | Q29615623 | ||
| Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin | Q29615684 | ||
| Parkinson's disease | Q29616302 | ||
| α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies | Q30471591 | ||
| DJ-1 is critical for mitochondrial function and rescues PINK1 loss of function | Q30495575 | ||
| SNCA variant associated with Parkinson disease and plasma alpha-synuclein level | Q30497763 | ||
| Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy | Q33444800 | ||
| Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. | Q33594388 | ||
| Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis | Q33595218 | ||
| Lysosomal degradation of alpha-synuclein in vivo. | Q33810012 | ||
| Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients | Q33861614 | ||
| SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease | Q33944220 | ||
| A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. | Q33982546 | ||
| DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy | Q34399382 | ||
| Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity | Q34636872 | ||
| The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization | Q34836156 | ||
| α-Synuclein impairs macroautophagy: implications for Parkinson's disease. | Q35005567 | ||
| Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis | Q35058315 | ||
| VPS35 mutations in Parkinson disease | Q35103751 | ||
| Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers | Q35119612 | ||
| Aggregation of α-synuclein in S. cerevisiae is associated with defects in endosomal trafficking and phospholipid biosynthesis | Q35138501 | ||
| Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway | Q35344983 | ||
| Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning | Q35771011 | ||
| Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons | Q35807528 | ||
| Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders | Q35960413 | ||
| The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis | Q36423369 | ||
| Physiological and pathological properties of alpha-synuclein | Q36866952 | ||
| Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. | Q37102231 | ||
| A multidisciplinary study of patients with early-onset PD with and without parkin mutations | Q37180446 | ||
| A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine | Q37343442 | ||
| Genomic investigation of alpha-synuclein multiplication and parkinsonism | Q37362778 | ||
| Association of glucocerebrosidase mutations with dementia with lewy bodies | Q37379711 | ||
| Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease | Q37402225 | ||
| Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. | Q39562553 | ||
| Pathogenic lysosomal depletion in Parkinson's disease | Q39655523 | ||
| Inhibition of mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1. | Q39655865 | ||
| Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity | Q39914071 | ||
| alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome | Q43816254 | ||
| α-Synuclein Is Degraded by Both Autophagy and the Proteasome | Q44420467 | ||
| Young-onset Parkinson's disease revisited--clinical features, natural history, and mortality | Q44667840 | ||
| Aberrant phosphorylation of alpha-synuclein in human Niemann-Pick type C1 disease | Q44852325 | ||
| Localization of MAP1-LC3 in vulnerable neurons and Lewy bodies in brains of patients with dementia with Lewy bodies | Q46184361 | ||
| Neuronal and glial accumulation of alpha- and beta-synucleins in human lipidoses | Q46314049 | ||
| Neuropathology provides clues to the pathophysiology of Gaucher disease | Q47247270 | ||
| PINK1-linked parkinsonism is associated with Lewy body pathology | Q48252842 | ||
| The ups and downs of alpha-synuclein mRNA expression | Q48375102 | ||
| Glucocerebrosidase mutations are an important risk factor for Lewy body disorders | Q48491146 | ||
| Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases | Q48494226 | ||
| Neurodegenerative disease: amyloid pores from pathogenic mutations | Q48544171 | ||
| Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. | Q48586171 | ||
| Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study | Q53612457 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 1364-1369 | |
| P577 | publication date | 2012-08-23 | |
| P1433 | published in | Movement Disorders | Q1486418 |
| P1476 | title | Lysosome-dependent pathways as a unifying theme in Parkinson's disease | |
| P478 | volume | 27 |
| Q47157967 | A Critical Assessment of Exosomes in the Pathogenesis and Stratification of Parkinson's Disease. |
| Q58803163 | A new hypothesis for Parkinson's disease pathogenesis: GTPase-p38 MAPK signaling and autophagy as convergence points of etiology and genomics |
| Q39006154 | A switchable peptide sensor for real-time lysosomal tracking |
| Q35138593 | ATP6V0C knockdown in neuroblastoma cells alters autophagy-lysosome pathway function and metabolism of proteins that accumulate in neurodegenerative disease |
| Q27323098 | Alpha-Synuclein Induces Lysosomal Rupture and Cathepsin Dependent Reactive Oxygen Species Following Endocytosis |
| Q38155480 | Animal models of Parkinson's disease: a gateway to therapeutics? |
| Q45591469 | Calcium dysregulation in Parkinson’s disease |
| Q35865171 | Can the disease course in Parkinson's disease be slowed? |
| Q49569836 | Capturing intracellular Ca2+ dynamics in computational models of neurodegenerative diseases |
| Q99565627 | Cargo and cell-specific differences in extracellular vesicle populations identified by multiplexed immunofluorescent analysis |
| Q27003886 | Cellular function and pathological role of ATP13A2 and related P-type transport ATPases in Parkinson's disease and other neurological disorders |
| Q38225786 | Defective autophagy in Parkinson's disease: lessons from genetics |
| Q37181996 | Deubiquitinase Usp8 regulates α-synuclein clearance and modifies its toxicity in Lewy body disease. |
| Q38107478 | Dysfunction of the autophagy/lysosomal degradation pathway is a shared feature of the genetic synucleinopathies |
| Q36678823 | ER Stress and Autophagic Perturbations Lead to Elevated Extracellular α-Synuclein in GBA-N370S Parkinson's iPSC-Derived Dopamine Neurons. |
| Q48181256 | Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons. |
| Q38773604 | Endocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid proteins |
| Q37706391 | Enhanced ubiquitin-dependent degradation by Nedd4 protects against α-synuclein accumulation and toxicity in animal models of Parkinson's disease. |
| Q34483905 | Function and dysfunction of two-pore channels |
| Q38164878 | Genetic causes of Parkinson's disease and their links to autophagy regulation |
| Q50251968 | Genetics of movement disorders |
| Q64073224 | Glial phagocytic clearance in Parkinson's disease |
| Q27005669 | Glucocerebrosidase and Parkinson disease: Recent advances |
| Q24337392 | Glucocerebrosidase is shaking up the synucleinopathies |
| Q37696004 | Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models |
| Q33827945 | High expression levels of the D686N Parkinson's disease mutation in VPS35 induces α-synuclein-dependent toxicity in yeast |
| Q39760969 | Identification of distinct circulating exosomes in Parkinson's disease |
| Q91715341 | Insight into the Role of Extracellular Vesicles in Lysosomal Storage Disorders |
| Q38588014 | Insights from late-onset familial parkinsonism on the pathogenesis of idiopathic Parkinson's disease |
| Q36304737 | Integrated analysis of genetic, behavioral, and biochemical data implicates neural stem cell-induced changes in immunity, neurotransmission and mitochondrial function in Dementia with Lewy Body mice. |
| Q64791386 | LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease |
| Q38869514 | LRRK2 and Autophagy |
| Q28555118 | Lysosomal Re-acidification Prevents Lysosphingolipid-Induced Lysosomal Impairment and Cellular Toxicity |
| Q37461364 | Lysosomal impairment in Parkinson's disease |
| Q38260329 | Mechanism and Regulation of Autophagy and Its Role in Neuronal Diseases |
| Q34100399 | Mutations in the ATP13A2 gene and Parkinsonism: a preliminary review |
| Q38580816 | Neuropathology of α-synuclein propagation and braak hypothesis |
| Q39570564 | Neuroprotective Effects of Paeoniflorin on 6-OHDA-Lesioned Rat Model of Parkinson's Disease |
| Q28538079 | Niemann-Pick C disease gene mutations and age-related neurodegenerative disorders |
| Q52559939 | Parkinson Disease from Mendelian Forms to Genetic Susceptibility: New Molecular Insights into the Neurodegeneration Process. |
| Q38727638 | Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance |
| Q92586699 | Parkinsonism and Other Movement Disorders Associated with Chediak-Higashi Syndrome: Case Report and Systematic Literature Review |
| Q37738863 | Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease |
| Q48619578 | Proteolysis of α-synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology |
| Q91644975 | Proteomic and functional analyses in disease models reveal CLN5 protein involvement in mitochondrial dysfunction |
| Q30844860 | Quantitative proteomic analysis of Parkin substrates in Drosophila neurons. |
| Q104495786 | Selected peptide-based fluorescent probes for biological applications |
| Q37236525 | Silencing synuclein at the synapse with PLK2 |
| Q41882309 | Surfactant secretion in LRRK2 knock-out rats: changes in lamellar body morphology and rate of exocytosis. |
| Q35083383 | Synaptojanin 1 is required for endolysosomal trafficking of synaptic proteins in cone photoreceptor inner segments |
| Q38620227 | Targeting the Autophagy/Lysosomal Degradation Pathway in Parkinson's Disease. |
| Q40998960 | The Coordinated Action of Calcineurin and Cathepsin D Protects Against α-Synuclein Toxicity. |
| Q39319763 | The Role of Astrocyte Dysfunction in Parkinson's Disease Pathogenesis |
| Q51284194 | The Transcellular Propagation and Intracellular Trafficking of α-Synuclein. |
| Q38093808 | The VPS35 gene and Parkinson's disease |
| Q38222396 | The expanding universe of disorders of the basal ganglia |
| Q34336776 | The pallidopyramidal syndromes: nosology, aetiology and pathogenesis |
| Q27024152 | Treating Parkinson's disease in the 21st century: can stem cell transplantation compete? |
| Q92861469 | Vesicular Dysfunction and the Pathogenesis of Parkinson's Disease: Clues From Genetic Studies |
Search more.